Product Description
Zhongsheng Pharmaceutical is developing zsp-1602, an Oral SMO Inhibitor for basal cell carcinoma, adenocarcinoma of esophagogastric junction, small cell lung cancer, neuroendocrine neoplasm and other advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03734913)
Mechanisms of Action: SMO Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Neuroendocrine Tumors|Medulloblastoma|Basal Cell Carcinoma|Small Cell Lung Cancer|Esophageal Cancer|Glioblastoma|Gastrointestinal Cancer|Neuroendocrine Carcinoma|Adenocarcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ZSP1602-16-01 | P1 |
Unknown status |
Medulloblastoma|Basal Cell Carcinoma|Gastrointestinal Cancer|Small Cell Lung Cancer|Adenocarcinoma|Esophageal Cancer|Neuroendocrine Tumors|Glioblastoma|Neuroendocrine Carcinoma |
2021-07-31 |
41% |
CTR20181036 | P1 |
Unknown Status |
Neuroendocrine Tumors|Medulloblastoma|Basal Cell Carcinoma|Small Cell Lung Cancer|Esophageal Cancer|Glioblastoma|Gastrointestinal Cancer|Neuroendocrine Carcinoma |
None |